{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:16:31Z","timestamp":1790201791864,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T18:15:40Z","timestamp":1532369740000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Burkitt lymphoma- a rare but challenging lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beha.2018.07.013_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11899-015-0263-4","article-title":"Treating burkitt lymphoma in adults","volume":"10","author":"Casulo","year":"2015","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"6","key":"10.1016\/j.beha.2018.07.013_bib2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","article-title":"Epidemiology: clues to the pathogenesis of Burkitt lymphoma","volume":"156","author":"Magrath","year":"2012","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.beha.2018.07.013_bib3","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.013_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2018.07.013_bib5","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1182\/blood-2012-07-440073","article-title":"Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases","volume":"120","author":"Laurini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.013_bib6","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21357","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"10.1016\/j.beha.2018.07.013_bib7","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.013_bib8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol Offic J Eur Soc Med Oncol\/ESMO"},{"issue":"25","key":"10.1016\/j.beha.2018.07.013_bib9","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","article-title":"AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and\/or biology?","volume":"116","author":"Guech-Ongey","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.07.013_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann Oncol Offic J Eur Soc Med Oncol\/ESMO"},{"issue":"9","key":"10.1016\/j.beha.2018.07.013_bib11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0002-9343(01)01020-8","article-title":"Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes","volume":"111","author":"Gabarre","year":"2001","journal-title":"Am J Med"},{"issue":"21","key":"10.1016\/j.beha.2018.07.013_bib12","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of Burkitt's lymphoma","volume":"18","author":"Hecht","year":"2000","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2018.07.013_bib13","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2018.07.013_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"Salaverria","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2018.07.013_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/bloodadvances.2016000794","article-title":"High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis","volume":"1","author":"Lombardo","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.beha.2018.07.013_bib16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"7418","key":"10.1016\/j.beha.2018.07.013_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.beha.2018.07.013_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.013_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2141.2012.09026.x","article-title":"Burkitt lymphoma: staging and response evaluation","volume":"156","author":"Sandlund","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.013_bib20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.013_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.beha.2018.07.013_bib22","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.07.013_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2018.07.013_bib24","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol Offic J Eur Soc Med Oncol\/ESMO"},{"issue":"3","key":"10.1016\/j.beha.2018.07.013_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.013_bib26","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.beha.2018.07.013_bib27","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"10036","key":"10.1016\/j.beha.2018.07.013_bib28","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2018.07.013_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.07.013_bib30","first-page":"945","article-title":"Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma","volume":"19","author":"van Imhoff","year":"2005","journal-title":"Leukemia Offic J Leuk Soc Am Leuk Res Fund UK"},{"issue":"6","key":"10.1016\/j.beha.2018.07.013_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2141.2006.06080.x","article-title":"Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma","volume":"133","author":"Song","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.013_bib32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Haioun","year":"1997","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.013_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2018.07.013_bib34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.beha.2018.07.013_bib35","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1038\/bcj.2013.24","article-title":"BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia","volume":"3","author":"Da Costa","year":"2013","journal-title":"Blood Canc J"},{"issue":"7","key":"10.1016\/j.beha.2018.07.013_bib36","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00277-008-0642-1","article-title":"Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome","volume":"88","author":"Choi","year":"2009","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.013_bib37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with burkitt and burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T15:02:18Z","timestamp":1720450938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300525"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.013","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burkitt lymphoma- a rare but challenging lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}